| 新发重大传染病的临床治疗药物应对:超说明书用药与同情用药 |
| |
| 引用本文： | 李竺蔓,郭芷君,徐峰. 新发重大传染病的临床治疗药物应对:超说明书用药与同情用药[J]. 药学实践杂志, 2020, 38(3): 207-210 |
| |
| 作者姓名： | 李竺蔓 郭芷君 徐峰 |
| |
| 作者单位： | 南方医科大学附属奉贤医院, 上海 201400 |
| |
| 基金项目： | 上海市临床药学重点专科建设项目（2018—2020） |
| |
| 摘 要： | 目前,由新型冠状病毒(SARS-CoV-2)导致的肺炎(COVID-19)尚无针对性治疗药物,临床主要选择干扰素、洛匹那韦/利托那韦、利巴韦林、磷酸氯喹、阿比多尔等超说明书用药和瑞德西韦同情用药。为此,对这两种临床用药应对行为给予评述。
|
| 关 键 词： | 治疗药物应对 新发重大传染病 超说明书用药 同情用药 |
| 收稿时间： | 2020-03-07 |
| 修稿时间： | 2020-04-27 |
Clinical medication response under new major infectious disease: off-label use and compassionate use |
| |
| LI Zhuman,GUO Zhijun,XU Feng. Clinical medication response under new major infectious disease: off-label use and compassionate use[J]. The Journal of Pharmaceutical Practice, 2020, 38(3): 207-210 |
| |
| Authors: | LI Zhuman GUO Zhijun XU Feng |
| |
| Affiliation: | Fengxian Hospital, Southern Medical University, Shanghai 201400, China |
| |
| Abstract: | At present, there are no specific targeted drugs for the treatment of pneumonia (COVID-19) caused by the novel coronavirus (SARS-CoV-2). Interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate were chosen as off-label use, and remdesivir was chosen as compassionate use. This paper reviewed the behavior of the two medication response to the new major infectious disease. |
| |
| Keywords: | medication response new major infectious disease off-label use compassionate use |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《药学实践杂志》浏览原始摘要信息 |
|
点击此处可从《药学实践杂志》下载免费的PDF全文 |
